Published in Blood on March 15, 2007
Role of platelet-derived growth factors in physiology and medicine. Genes Dev (2008) 8.89
Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood (2009) 2.50
Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood (2011) 2.33
Current issues in chronic graft-versus-host disease. Blood (2014) 1.83
Allogeneic HY antibodies detected 3 months after female-to-male HCT predict chronic GVHD and nonrelapse mortality in humans. Blood (2015) 1.57
Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group. Blood (2007) 1.36
Murine models of chronic graft-versus-host disease: insights and unresolved issues. Biol Blood Marrow Transplant (2008) 1.32
Allogeneic hematopoietic cell transplantation: the state of the art. Expert Rev Hematol (2010) 1.16
Mouse models of graft-versus-host disease: advances and limitations. Dis Model Mech (2011) 1.16
Oral graft-versus-host disease. Oral Dis (2008) 1.14
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report. Biol Blood Marrow Transplant (2015) 1.12
Pathogenesis and management of graft-versus-host disease. Immunol Allergy Clin North Am (2010) 1.10
Aberrant B-cell homeostasis in chronic GVHD. Blood (2015) 1.06
Regulation of platelet-derived growth factor receptor function by integrin-associated cell surface transglutaminase. J Biol Chem (2009) 1.03
A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies. Blood (2011) 1.01
Biology of chronic graft-versus-host disease: implications for a future therapeutic approach. Keio J Med (2008) 0.99
Cutaneous chronic graft-versus-host disease does not have the abnormal endothelial phenotype or vascular rarefaction characteristic of systemic sclerosis. PLoS One (2009) 0.99
B cells in chronic graft-versus-host disease. Biol Blood Marrow Transplant (2014) 0.99
Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. Blood (2015) 0.97
Chronic graft-versus-host disease (GVHD) in children. Pediatr Clin North Am (2010) 0.94
A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation. Clin Cancer Res (2015) 0.92
Biologic markers of chronic GVHD. Bone Marrow Transplant (2013) 0.91
The isomorphic response in morphealike chronic graft-vs-host disease. Arch Dermatol (2008) 0.90
Oral chronic graft-versus-host disease: current pathogenesis, therapy, and research. Oral Dis (2012) 0.87
The pathophysiology of chronic graft-versus-host disease: the unveiling of an enigma. Korean J Hematol (2011) 0.86
Antibodies from donor B cells perpetuate cutaneous chronic graft-versus-host disease in mice. Blood (2016) 0.85
Validation of new biomarkers in systemic autoimmune diseases. Nat Rev Rheumatol (2011) 0.81
Coagulation and autoimmunity in scleroderma interstitial lung disease. Semin Arthritis Rheum (2010) 0.80
Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease. Biol Blood Marrow Transplant (2015) 0.80
Oxidative Stress and Skin Fibrosis. Curr Pathobiol Rep (2014) 0.80
B cells and transplantation: an educational resource. Biol Blood Marrow Transplant (2009) 0.80
NADPH oxidase enzymes in skin fibrosis: molecular targets and therapeutic agents. Arch Dermatol Res (2013) 0.79
Physical function and quality of life in patients with chronic GvHD: a summary of preclinical and clinical studies and a call for exercise intervention trials in patients. Bone Marrow Transplant (2015) 0.78
Tirosin kinase inhibitors in chronic graft versus host disease: from bench to bedside. ScientificWorldJournal (2011) 0.78
Chronic graft-versus-host disease: biological insights from pre-clinical and clinical studies. Blood (2016) 0.78
Augmentation of Recipient Adaptive Alloimmunity by Donor Passenger Lymphocytes within the Transplant. Cell Rep (2016) 0.77
Biomarkers in chronic graft-versus-host disease. Expert Rev Hematol (2011) 0.77
Progressive Bronchiectasis as a Manifestation of Chronic Graft Versus Host Disease Following Bone Marrow Transplantation. Radiol Case Rep (2015) 0.77
Lack of association of platelet-derived growth factor (PDGF) receptor autoantibodies and severity of chronic graft-versus-host disease (GvHD). J Cancer Res Clin Oncol (2013) 0.76
Tyrosine kinases in inflammatory dermatologic disease. J Am Acad Dermatol (2010) 0.76
Systemic sclerosis immunoglobulin induces growth and a pro-fibrotic state in vascular smooth muscle cells through the epidermal growth factor receptor. PLoS One (2014) 0.76
Fibrotic and sclerotic manifestations of chronic graft-versus-host disease. Biol Blood Marrow Transplant (2012) 0.75
Anti-CD13 Abs in children with extensive chronic GVHD and their relation to soluble CD13 after allogeneic blood and marrow transplantation from a Children's Oncology Groups Study, ASCT0031. Bone Marrow Transplant (2010) 0.75
Rippled skin, fasciitis, and joint contractures. J Am Acad Dermatol (2008) 0.75
Approaches for the prevention of graft-versus-host disease following hematopoietic cell transplantation. Int J Hematol Oncol (2015) 0.75
Old game, new players: Linking classical theories to new trends in transplant immunology. World J Transplant (2017) 0.75
Biology of chronic graft-vs-host disease: Immune mechanisms and progress in biomarker discovery. World J Transplant (2016) 0.75
Proteasome: target for acute and chronic GVHD? Blood (2014) 0.75
Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet (2008) 12.59
Scleroderma. N Engl J Med (2009) 6.50
2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum (2013) 5.99
Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med (2006) 4.46
Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood (2003) 3.88
Management of minor head injury in patients receiving oral anticoagulant therapy: a prospective study of a 24-hour observation protocol. Ann Emerg Med (2012) 3.55
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis (2013) 3.11
DNA oxidation as triggered by H3K9me2 demethylation drives estrogen-induced gene expression. Science (2008) 3.09
False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin-tazobactam. Clin Infect Dis (2004) 3.06
Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica (2007) 3.03
The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Transplant (2006) 2.93
Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant (2005) 2.82
Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncol (2008) 2.70
Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood (2009) 2.51
A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood (2008) 2.44
DNA damage, homology-directed repair, and DNA methylation. PLoS Genet (2007) 2.29
Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial. Lancet Oncol (2010) 2.25
Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT). Blood (2007) 2.09
Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol (2009) 2.04
Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood (2002) 2.03
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood (2011) 2.02
Regional Implantation of Autologous Adipose Tissue-Derived Cells Induces a Prompt Healing of Long-Lasting Indolent Digital Ulcers in Patients With Systemic Sclerosis. Cell Transplant (2014) 2.02
Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Haematologica (2008) 1.97
Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol (2002) 1.97
Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood (2011) 1.96
Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant (2012) 1.89
Risk of non-Hodgkin lymphoma in celiac disease. JAMA (2002) 1.81
Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome. Haematologica (2008) 1.80
Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation. Blood (2009) 1.74
Boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation. Haematologica (2006) 1.73
Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood (2002) 1.68
Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide. Biol Blood Marrow Transplant (2008) 1.67
Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma. Biol Blood Marrow Transplant (2011) 1.66
Helical tomotherapy targeting total bone marrow after total body irradiation for patients with relapsed acute leukemia undergoing an allogeneic stem cell transplant. Radiother Oncol (2011) 1.63
Mitochondrial AKAP121 links cAMP and src signaling to oxidative metabolism. Mol Biol Cell (2005) 1.62
DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis. Leuk Lymphoma (2006) 1.61
Genetic polymorphisms of CYP3A4, GSTT1, GSTM1, GSTP1 and NQO1 and the risk of acquired idiopathic aplastic anemia in Caucasian patients. Haematologica (2005) 1.56
Microcirculatory effects of the transfusion of leukodepleted or non-leukodepleted red blood cells in patients with sepsis: a pilot study. Crit Care (2014) 1.56
Risk assessment of patients with hematologic malignancies who develop fever accompanied by pulmonary infiltrates: a historical cohort study. Cancer (2004) 1.54
Development of leukemia in donor cells after allogeneic stem cell transplantation--a survey of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica (2005) 1.45
Performance of the preliminary classification criteria for cryoglobulinaemic vasculitis and clinical manifestations in hepatitis C virus-unrelated cryoglobulinaemic vasculitis. Clin Exp Rheumatol (2012) 1.41
A T-cell epitope encoded by a subset of HLA-DPB1 alleles determines nonpermissive mismatches for hematologic stem cell transplantation. Blood (2003) 1.40
Role of viral infections in the etiopathogenesis of systemic sclerosis. Clin Exp Rheumatol (2013) 1.40
A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. Blood (2005) 1.39
Human dedifferentiated adipocytes show similar properties to bone marrow-derived mesenchymal stem cells. Stem Cells (2012) 1.38
A policy for the disposal of autologous hematopoietic progenitor cells: report from an Italian consensus panel. Transfusion (2014) 1.38
Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood (2003) 1.37
Mitochondrial AKAP121 binds and targets protein tyrosine phosphatase D1, a novel positive regulator of src signaling. Mol Cell Biol (2004) 1.33
Aplastic anemia: pathophysiology and treatment. Biol Blood Marrow Transplant (2009) 1.32
cAMP-PKA signaling to the mitochondria: protein scaffolds, mRNA and phosphatases. Cell Signal (2005) 1.31
Essential role of A-kinase anchor protein 121 for cAMP signaling to mitochondria. J Biol Chem (2002) 1.31
Bone marrow endothelial progenitors are defective in systemic sclerosis. Arthritis Rheum (2006) 1.30
Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. Haematologica (2009) 1.28
PKA-dependent binding of mRNA to the mitochondrial AKAP121 protein. J Mol Biol (2003) 1.26
Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun Rev (2011) 1.26
Platelet-derived growth factor and reactive oxygen species (ROS) regulate Ras protein levels in primary human fibroblasts via ERK1/2. Amplification of ROS and Ras in systemic sclerosis fibroblasts. J Biol Chem (2005) 1.26
Blood stream infections in allogeneic hematopoietic stem cell transplant recipients: reemergence of Gram-negative rods and increasing antibiotic resistance. Biol Blood Marrow Transplant (2009) 1.25
Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD. Blood (2013) 1.24
Aspergillus galactomannan antigen in the cerebrospinal fluid of bone marrow transplant recipients with probable cerebral aspergillosis. J Clin Microbiol (2002) 1.22
Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: the European Group for Blood and Marrow Transplantation experience. Blood (2013) 1.21
Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial. Haematologica (2005) 1.21
Influence of donor/recipient sex matching on outcome of allogeneic hematopoietic stem cell transplantation for aplastic anemia. Transplantation (2006) 1.21
Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party. Blood (2012) 1.20
Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. Blood (2014) 1.19
Unrelated cord blood transplantation: outcomes after single-unit intrabone injection compared with double-unit intravenous injection in patients with hematological malignancies. Transplantation (2013) 1.18
Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood (2005) 1.18
Reactive oxygen species are required for maintenance and differentiation of primary lung fibroblasts in idiopathic pulmonary fibrosis. PLoS One (2010) 1.15
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. N Engl J Med (2015) 1.15
Female genital tract graft-versus-host disease following allogeneic bone marrow transplantation. Haematologica (2003) 1.15
Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation. Haematologica (2009) 1.11
Results and follow-up of a phase III randomized study of recombinant human-granulocyte stimulating factor as support for immunosuppressive therapy in patients with severe aplastic anaemia. Br J Haematol (2002) 1.11
Hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria: long-term results of a retrospective study on behalf of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Haematologica (2009) 1.10
Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. Arthritis Rheum (2002) 1.10
(1-3)-β-D-glucan in cerebrospinal fluid is useful for the diagnosis of central nervous system fungal infections. Clin Infect Dis (2013) 1.09